• 1
    Soares-Weiser K, Bravo Vergel Y, Beynon S et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:iiiiv, ix-206.
  • 2
    National Institute for Health and Clinical Excellence (NICE). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care (Issue date: July 2006). Available at: Last accessed 31st July 2013.
  • 3
    Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315331.
  • 4
    Cipriani A, Geddes JR. What is a run-in phase? Epidemiol Psichiatr Soc 2010;19:2122.
  • 5
    Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998;279:222225.
  • 6
    Berger VW, Rezvani A, Makarewicz VA. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 2003;24:156166.
  • 7
    Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:13061315.
  • 8
    European Medicines Agency. Committee for proprietary medicinal products: note for Guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder, April 2001. Available at:
  • 9
    Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626637.
  • 10
    Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247256.
  • 11
    Vieta E, Suppes T, Eggens I et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251263.
  • 12
    Suppes T, Vieta E, Liu S et al. Maintenance treatment for patients with bipolar I disorder: results from a north American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476488.
  • 13
    Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130137.
  • 14
    Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133144.
  • 15
    Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337345.
  • 16
    Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:12811290.
  • 17
    Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry 2011;72:14521464.
  • 18
    Carlson BX, Ketter TA, Sun W et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:4153.
  • 19
    Ivanova A, Tamura RN. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res 2011. doi: 10.1177/0962280211431023 [Epub ahead of print].
  • 20
    Fedorov VV, Liu T. Enrichment design. In: D'Agostino RB, Sullivan LM, Massoro JM, eds. Wiley encyclopedia of clinical trials. Hoboken, NJ: John Wiley & Sons, Inc, 2007. doi: 10.1002/9780471462422.eoct342.
  • 21
    Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 2010;24:17291738.
  • 22
    Calabrese JR, Rapport DJ, Shelton MD, Kimmel SE. Evolving methodologies in bipolar disorder maintenance research. Br J Psychiatry 2001;178:S157S163.
  • 23
    Bowden CL, Swann AC, Calabrese JR et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997;33:693699.
  • 24
    Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385395.
  • 25
    Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ 2011;342:d2291.
  • 26
    Bulloch AG, Bresee LC, Beck CA, Patten SB. Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002–2010. Can J Psychiatry 2012;57:263268.
  • 27
    Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 2011;20:177184.
  • 28
    Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy 2006;26:11341147.
  • 29
    Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:14801491.